Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH)

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 18, 2014, Pages 2736-2741

  Surapaneni, K M ^a   Priya, V V ^b   Mallika, J ^c  

^a SAVEETHA MEDICAL COLLEGE AND HOSPITAL   (India)

^b SAVEETHA UNIVERSITY   (India)

^c SSN COLLEGE OF ENGINEERING   (India)

Author keywords

CYP2E1; Cytochrome; Hydroxy citric acid; Non alcoholic fatty liver disease (NAFLD); Non Alcoholic Steatohepatitis (NASH); Pioglitazone; Quercetin

Indexed keywords

CYTOCHROME P450 2E1; HYDROXYCITRIC ACID; PIOGLITAZONE; QUERCETIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOXIDANT; CITRIC ACID; ENZYME INHIBITOR; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; ENZYME BLOOD LEVEL; IMMUNOBLOTTING; LIPID DIET; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; RAT; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PHYSIOLOGY; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; CITRIC ACID; CYTOCHROME P-450 CYP2E1; ENZYME INHIBITORS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; QUERCETIN; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84925376931     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. ADAMS LA, LYMP J F, ST SAUVER J, SANDERSON SO, LINDOR KD, FELDSTEIN A, ANGULO P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
2. CHARLTON M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-1058.
3. AHMED MH, BYRNE CD. Non-alcoholic steatohepati-tis. In: Byrne CD, Wild S, editors. Metabolic syndrome. Chichester: John Wiley & Sons, 2005; pp. 279-305.
4. PASCALE A, PAIS R, RATZIU V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointest Liver Dis 2010;19:415.
5. BEGRICHE K, IGOUDJIL A, PESSAYRE D, FROMENTY B. Mi-tochondrial dysfunction in NASH: Causes, consequences and possible means to prevent it. Mitochondrion 2006;6:1-28.
6. WEI Y, CLARK SE, THYFAULT J P, UPTERGROVE GM, LI W, WHALEY-CONNELL AT, FERRARIO CM, SOWERS JR, IBDAH JA. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol 2009;13:1329-1337.
7. ARTHUR J. McCullough. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40:S17-S29.
8. TIROSH A, RUDICH A, POTASHNIK R, BASHAN N. Oxida-tive stress impairs insulin but not platelet-derived growth factor signalling in 3T3-L1 adipocytes. Biochem J 2001;355(Pt 3):s757-763.
9. EMERY MG, FISHER JM, CHIEN JY, KHARASCH ED, DELLINGER E P, KOWDLEY K V, THUMMEL KE. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003;38:428-435.
10. EKSTRÖM G, INGELMAN-SUNDBERG M. Rat liver micro-somal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol 1989;38:1313-1319.
11. RONIS MJJ, LINDROS KO, INGELMAN-SUNDBERG M. The CYP2E1 family. In: C. Ioannides, editor. Cytochrome P-450: metabolic and toxicological aspects. CRC Press, Boca Raton, FL, 1996; pp. 211-239.
12. LIEBER CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997;77:517-544.
13. SURAPANENI KM, JAINU M. Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomark-ers in non alcoholic steatohepatitis. Pharmacog-nosy Res 2014;6:153-162.
14. SURAPANENI KM, JAINU M. Effect of pioglitazone, quercetin, and hydroxy citric acid on the lipid profile and lipoproteins in experimentally induced non-alcoholicsteatohepatitis (NASH). Indian J Pharm Educ Res 2014;48:32-38.
15. SURAPANENI KM, JAINU M. Comparative effect of pi-oglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis. J Physiol Pharmacol 2014;65:67-74.
16. SURAPANENI KM, SARASWATHI P, JAINU M. Non alcoholic steatohepatitis (NASH) experimental model induction in rats. Int J Pharm Bio Sci 2012;3: (B) 1085-1090.
17. SURAPANENI K M, SARSWATHI P, JAINU M. Role of pi-oglitazone, quercetin and hydroxy citric acid against non alcoholic steatohepatitis (NASH)-histological and scanning electron microscopy (SEM) studies in an experimental model of NASH. Asian J Pharm Clin Res 2012;5:244-247.
18. DAI Y, RASHBA-STEP J, CEDERBAUM AI. Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 1993;32:6928-6937.
19. ESTEBAUER H. Cytotoxicity and genotoxicity of lipid-oxidation products. Am J Clin Nutr 1996;57:779S-785S.
20. KONO H, BRADFORD BU, YIN M, SULIK KK, KOOP DR, PETERS JM, GONZALES FJ, MCDONALD T, DIKALOVA A, KANDIJSKA MB, THURMAN RG. CYP2E1 is not involved in early alcohol-induced liver injury. Am J Physiol 1999;277:G1259-G1267.
21. TIETZ N. Total lipids. In: N. Teitz, editor. Fundamentals of clinical chemistry. W. B. Saunders Co. Philadelphia, 1976; pp. 492-494.
22. BELL DR, PLANT NJ, RIDER CG, NA L, BROWN S, ATEITALLA I, ACHARYA SK, DAVIES MH, ELIAS E, JENKINS NA, ET AL. Species-specific induction of cy-tochrome P-450 4A RNAs: PCR cloning of partial guinea-pig, human and mouse CYP4A cDNAs. Biochem J 1993;294:173-180.
23. OBERTSON G, LECLERCQ I, FARRELL GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gas-trointest Liver Physiol 2001;281:G1135-G1139.
24. SCHATTENBERG JM, WANG Y, SINGH R, RIGOLI RM, CZAJA MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005;280:9887-9894.
25. WELTMAN MD, FARRELL GC, LIDDLE C. Increased he-patocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645-1653.
26. WELTMAN MD, FARRELL GC, HALL P, INGELMAN-SUNDBERG M, LIDDLE C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steato-hepatitis. Hepatology 1998;27:128-133.
27. ERSOY C, KIYICI S, BUDAK F, ORAL B, GUCLU M, DURAN C, SELIMOGLU H, ERTUR E, TUNCEL E, IMAMOGLU S. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res Clin Pract 2008;81:56-60.
28. DEVASAGAYAM TA, MISHRA A, BAPAT MA, TILAK JC. An-tioxidant activity of Garcinia indica (kokam) and its syrup. Curr Sci 2006;91:90-93.
29. TANG YH, GAO C, SHI YR, ZHU L P, HU XM, WANG D, LV Y, YANG X F, LIU LG, YAO P. Quercetin attenuates ethanol-derived microsomal oxidative stress: Implication of haem oxygenase-1 induction. Food Chem 2012;132:1769-1774.
30. BENTZ AB. A review of quercetin: chemistry, antiox-idant properties, and bioavailability. JYI: Appalachian State University. [Online] April 1, 2009. [Cited: November 2, 2009.] http://www.jyi.org/re-search/re.php?id=3416
31. DAVIS JM, MURPHY EA, CARMICHAEL MD, DAVIS B. Quercetin increases brain and muscle mitochon-drial biogenesis and exercise tolerance. Am J Physiol Regul Integr Comp Physiol 2009;296:1071-1077.
32. DAVIS JM, MURPHY EA, CARMICHAEL MD. Effects of the dietary flavonoid quercetin upon performance and health. Curr Sports Med Rep 2009b; 8:206-213.
33. MILTON PRABU S, MUTHUMANI M, SHAGIRTHA K. Quercetin potentially attenuates cadmium induced oxidative stress mediated cardiotoxicity and dyslipidemia in rats. Eur Rev Med Pharmacol Sci 2013;17:582-595.
34. HARWOOD M, DANIELEWSKA-NIKIEL B, BORZELLECA J F, FLAMM GW, WILLIAMS GM, LINES TC. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45:2179-2205.
35. ANNAPURNA A, ANSARI MA, MANJUNATH PM. Partial role of multiple pathways in infarct size limiting effect of quercetin and rutin against cerebral is-chemia-reperfusion injury in rats. Eur Rev Med Pharmacol Sci 2013;17:491-500.